e23sFv-Fdt-tBid protein (State Key Laboratory of Cancer Biology)

N/A

Report date: 2025/03/19 20:00:56

Base Information

Drug Namee23sFv-Fdt-tBid protein (State Key Laboratory of Cancer Biology)
Drug Alias Nameanti-HER2 antibody fragment-immunotoxin conjugate (State Key Laboratory of Cancer Biology)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragmentBiologics > Protein drugs > Recombinant protein
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaPending
Originator CompaniesState Key Laboratory Of Cancer Biology
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesState Key Laboratory Of Cancer Biology
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A